Europe Tumor Ablation Market Report and Forecast 2025-2034

The Europe tumor ablation market size was valued at USD 0.30 Billion in 2024, driven by the rising preference for minimally invasive treatment procedures in the region. The market is expected to grow at a CAGR of 12.92% during the forecast period of 2025-2034, with the values likely to reach USD 1.01 Billion by 2034.

Europe Tumor Ablation Market Analysis

Tumor ablation is a minimally invasive procedure that uses extreme heat or cold to shrink or destroy tumors. It involves inserting a needle-tipped catheter into the tumor with the help of imaging guidance. The technological advancements along with the innovation of new procedures are expected to generate profitable opportunities, thereby, contributing to increased Europe tumor ablation market share.

The rising geriatric population and growing prevalence of cancer cases are amongst some of the most influential factors responsible for driving the growth of the market. After cardiovascular diseases, cancer is the most common cause of death and morbidity in Europe accounting for more than 3.7 million new cases and 1.9 million deaths each year in Europe. The market is also experiencing significant traction due to the rising demand for minimally invasive treatments and increasing awareness about ablation procedures, propelling the heightening of the Europe tumor ablation market demand.

In March 2024, Medtronic plc received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OsteoCool™ 2.0 bone tumor ablation system for the treatment of painful bone metastases and benign bone tumors such as osteoid osteoma. Integrated with several new features OsteoCool is poised to bring innovation to the market. Portfolio expansions by market players are expected to influence the Europe tumor ablation market size in the coming years.

The market is further influenced by the increasing number of research activities, and efforts of key players towards expanding their global footprint as well as enhance the existing technologies present in the market. In December 2023, Clinical Laserthermia Systems (CLS) announced participation in a new research study, called IRMPROFT, to examine the use of MRI in combination with biopsies to diagnose residual prostate cancer post-focal therapy. The company is participating in this study with their TRANBERG system, a cutting-edge solution for minimally invasive, image-guided focal laser ablation aimed at treating cancer. The application of tumor ablation in combination with other therapies is poised to drive market growth in the forecast period.

Europe Tumor Ablation Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Breakup by Technology

• Radiofrequency Ablation
• Microwave Ablation
• Cryoablation
• Irreversible Electroporation Ablation
• Other Ablation Technologies

Breakup by Application

• Kidney Cancer
• Liver Cancer
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Bone Cancer

Breakup by Mode of Treatment

• Surgical Ablation
• Laparoscopic Ablation
• Percutaneous Ablation

Breakup by End User

• Hospitals
• Cancer Specialty Clinics
• Others

Breakup by Region

• United Kingdom
• Germany
• France
• Italy

Europe Tumor Ablation Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• EDAP TMS
• Mermaid Medical
• BVM Medical Limited
• Cortex Technology
• Olympus Corporation
• BIOTRONIK SE & Co KG
• Boston Scientific Corporation
• Medtronic plc
• AngioDynamics, Inc.
• Merit Medical Systems, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

This product will be delivered within 3-5 business days.